Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MHRA Prioritises Science and Research Support as Part of New Corporate Plan

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
MHRA announced its aim to be a leading regulator on the world stage in supporting science and research as part of its new five-year corporate plan.

Alongside protecting and improving the health of millions of people everyday through effective regulation of medical products.

The plan has been developed using responses from stakeholders following a recent public consultation that was launched in December 2012. The five key themes the corporate plan concentrates on are:

•    The role of regulation and the regulator
•    Bringing innovation safely to market
•    Strengthening surveillance
•    Safe products and secure supply in globalised industries
•    Achieving excellence – a well run, efficient and effective organisation.

In April 2013, the MHRA family will expand with the transfer of the National Institute for Biological Standards and Control (NISBC) from the Health Protection Agency. This means the remit of the MHRA continues to grow and NIBSC will be an important part of the MHRA family alongside the Clinical Practice Research Datalink (CPRD), a world-class secure health research service launched in March 2012.

This corporate plan reflects the MHRA’s desire to lead regulatory matters globally and bring new innovative medicines and products safely to market. The MHRA’s new online Innovation Office recently launched, providing advice to manufacturers on the regulatory process.

This new plan will also help the MHRA to develop strategic processes where change is needed to improve core regulatory work including implementing new requirements to strengthen the surveillance and vigilance systems for medicines.

The corporate plan feeds into annual business plans setting out specific targets and activities that will contribute to the delivery of the corporate plan. One area of the 2013-14 business plan is major negotiations of new legislation relating to clinical trials and device regulation.

As part of its commitment to promoting growth, the MHRA has also devised a regulatory excellence programme which will aim to cut red tape and help industry achieve regulatory compliance.

MHRA Chief Executive, Professor Sir Kent Woods said:

“Our corporate plan sets out our key aim of protecting and enhancing the health of millions of people through better regulation of medicines and medical devices and promoting innovation.

“We have an exciting five years ahead with the introduction of the National Institute for Biological Standards and Control (NISBC) to the MHRA family this year and we are focused on achieving our aim of being a world leader in supporting science and research.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MHRA Appoints New Chief Executive
The Medicines and Healthcare Products Regulatory Agency (MHRA) announced the appointment of Dr Ian Hudson as its Chief Executive.
Friday, July 05, 2013
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!